{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:49:57Z","timestamp":1766738997183},"reference-count":180,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.numecd.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T17:50:41Z","timestamp":1455990641000},"page":"85-102","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Italian Society for the Study of Diabetes (SID)\/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly"],"prefix":"10.1016","volume":"26","author":[{"given":"M.G.","family":"Baroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pezzino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2016.02.001_bib1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Impaired \u03b2-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients","volume":"52","author":"Kasayama","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2265.2001.01206.x","article-title":"Relationship between blood pressure and glucose tolerance in acromegaly","volume":"54","author":"Jaffrain-Rea","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib5","first-page":"193","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.numecd.2016.02.001_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1563-2571.2000.00106.x","article-title":"Prevalence of diabetes in acromegaly and Cushing syndrome","volume":"27","author":"Biering","year":"2000","journal-title":"Acta Medica Austriaca"},{"key":"10.1016\/j.numecd.2016.02.001_bib8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","article-title":"Risk factors for glucose intolerance in active acromegaly","volume":"34","author":"Kreze","year":"2001","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.numecd.2016.02.001_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry","volume":"164","author":"Fieffe","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","article-title":"Acromegaly","volume":"26","author":"Nabarro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","article-title":"Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma","volume":"92","author":"Dekkers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.numecd.2016.02.001_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1507\/endocrj.43.645","article-title":"Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM","volume":"43","author":"Friedman","year":"1996","journal-title":"Endocr J"},{"key":"10.1016\/j.numecd.2016.02.001_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib18","doi-asserted-by":"crossref","first-page":"c54","DOI":"10.1159\/000097598","article-title":"Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases","volume":"105","author":"Uzu","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.numecd.2016.02.001_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1592\/phco.24.5.508.33355","article-title":"Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases","volume":"24","author":"Iwamoto","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.numecd.2016.02.001_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-13-0754","article-title":"Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?","volume":"170","author":"Giordano","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/diab.31.8.663","article-title":"Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization","volume":"31","author":"Rizza","year":"1982","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2016.02.001_bib22","first-page":"1012","article-title":"Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy","volume":"74","author":"Moller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00505182","article-title":"Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man","volume":"32","author":"Moller","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2016.02.001_bib24","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/diabetes.50.10.2301","article-title":"Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure","volume":"50","author":"Nielsen","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2016.02.001_bib25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1210\/jc.2002-020542","article-title":"Growth hormone replacement therapy induces insulin resistance by activating the glucose\u2013fatty acid cycle","volume":"88","author":"Bramnert","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1677\/joe.0.1610383","article-title":"Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone transgenic mice","volume":"161","author":"Dominici","year":"1999","journal-title":"J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib27","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1074\/jbc.272.11.7455","article-title":"Specific increase in p85alpha expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells","volume":"272","author":"Giorgino","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2016.02.001_bib28","doi-asserted-by":"crossref","first-page":"37489","DOI":"10.1074\/jbc.M506967200","article-title":"Increased p85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in\u00a0vivo insulin resistance associated with growth hormone excess","volume":"280","author":"Barbour","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2016.02.001_bib29","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/db06-0299","article-title":"Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance","volume":"56","author":"Del Rincon","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2016.02.001_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"Moller","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.numecd.2016.02.001_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","author":"van Raalte","year":"2009","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/dmr.5610040105","article-title":"Effects of glucocorticoids on carbohydrate metabolism","volume":"4","author":"McMahon","year":"1988","journal-title":"Diabetes Metab Rev"},{"key":"10.1016\/j.numecd.2016.02.001_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1152\/physrev.1984.64.1.170","article-title":"Hormonal regulation of hepatic gluconeogenesis","volume":"64","author":"Kraus-Friedman","year":"1984","journal-title":"Physiol Rev"},{"key":"10.1016\/j.numecd.2016.02.001_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/clnu.1999.0064","article-title":"Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man","volume":"19","author":"Dirlewanger","year":"2000","journal-title":"Clin Nutr"},{"key":"10.1016\/j.numecd.2016.02.001_bib35","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1172\/JCI116424","article-title":"Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in\u00a0vivo","volume":"91","author":"Giorgino","year":"1993","journal-title":"J Clin Investig"},{"issue":"Suppl. 1","key":"10.1016\/j.numecd.2016.02.001_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000314319","article-title":"Pathophysiology of diabetes mellitus in Cushing's syndrome","volume":"92","author":"Pivonello","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.numecd.2016.02.001_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1385\/ENDO:29:1:81","article-title":"Adipocyte-derived hormones, cytokines, and mediators","volume":"29","author":"Rondinone","year":"2006","journal-title":"Endocrine"},{"key":"10.1016\/j.numecd.2016.02.001_bib38","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib39","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1074\/jbc.272.6.3216","article-title":"Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids","volume":"272","author":"Gremlich","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2016.02.001_bib40","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1172\/JCI111141","article-title":"An in\u00a0vivo and in\u00a0vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects","volume":"72","author":"Pagano","year":"1983","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib41","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1073\/pnas.89.13.6035","article-title":"The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders","volume":"89","author":"Wajngot","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.numecd.2016.02.001_bib42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib43","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 4","key":"10.1016\/j.numecd.2016.02.001_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly \u2013 2011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.numecd.2016.02.001_bib45","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/BF03349217","article-title":"First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly Primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group","volume":"29","author":"Colao","year":"2006","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib46","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of octreotide pretreatment on surgical outcome in acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jcem.82.2.3648","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib48","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","article-title":"A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly","volume":"90","author":"Melmed","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib49","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1210\/jc.2003-030110","article-title":"Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results","volume":"88","author":"Cozzi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2265.2006.02467.x","article-title":"First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial","volume":"64","author":"Colao","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib51","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib52","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.02.001_bib53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1507\/endocrj.44.617","article-title":"Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy","volume":"44","author":"Wasada","year":"1997","journal-title":"Endocr J"},{"key":"10.1016\/j.numecd.2016.02.001_bib54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-10-1096","article-title":"Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved","volume":"164","author":"Kinoshita","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib55","doi-asserted-by":"crossref","first-page":"E823","DOI":"10.1152\/ajpendo.00020.2002","article-title":"Insulin action on protein metabolism in acromegalic patients","volume":"284","author":"Battezzati","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib56","first-page":"853","article-title":"Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels","volume":"36","author":"Mori","year":"2013","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/jc.2008-1546","article-title":"Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.03996.x","article-title":"Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues","volume":"75","author":"Tzanela","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","article-title":"Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study","volume":"15","author":"Giordano","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0028-3843(14)60103-1","article-title":"The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly","volume":"45","author":"Stelmachowska-Bana\u015b","year":"2011","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.numecd.2016.02.001_bib61","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1210\/jcem.85.10.6870","article-title":"Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center","volume":"85","author":"Barrande","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib62","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2265.2006.02513.x","article-title":"Gamma knife radiosurgery for acromegaly \u2013 long-term experience","volume":"64","author":"Jezkov\u00e1","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib63","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/jc.2013-3743","article-title":"Stereotactic radiosurgery for acromegaly","volume":"99","author":"Lee","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF03348242","article-title":"Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients","volume":"3","author":"Fedele","year":"1980","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.1981.tb00690.x","article-title":"The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly","volume":"15","author":"Feek","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib66","first-page":"100","article-title":"Bromocriptine and glucose tolerance in acromegalics","volume":"3","author":"Dolecek","year":"1982","journal-title":"Pharmatherapeutica"},{"key":"10.1016\/j.numecd.2016.02.001_bib67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2007-1018923","article-title":"Effect of long term bromocriptine treatment on glucose intolerance in acromegaly","volume":"14","author":"Chiba","year":"1982","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.numecd.2016.02.001_bib68","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF00186626","article-title":"Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion","volume":"71","author":"Rau","year":"1993","journal-title":"Clin Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib69","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ghir.2010.05.004","article-title":"The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment","volume":"20","author":"Roemmler","year":"2010","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.numecd.2016.02.001_bib70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib71","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1210\/jcem.87.4.8432","article-title":"A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal","volume":"87","author":"Parkinson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib72","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2016.02.001_bib73","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/bmj.299.6699.604","article-title":"Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly","volume":"299","author":"McKnight","year":"1989","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2016.02.001_bib74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1464-5491.1991.tb01644.x","article-title":"Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide","volume":"8","author":"James","year":"1991","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib75","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1530\/eje.0.1300581","article-title":"Effect of octreotide on glucose tolerance in acromegaly","volume":"130","author":"Koop","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib76","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-2007-979945","article-title":"Long-term effect of octreotide in acromegaly on insulin resistance","volume":"27","author":"Breidert","year":"1995","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.numecd.2016.02.001_bib77","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1530\/eje.0.1330430","article-title":"Effects of treatment with octreotide in acromegalic patients \u2013 a multicenter Italian study. Italian Multicenter Octreotide Study Group","volume":"133","author":"Arosio","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib78","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2169\/internalmedicine.36.319","article-title":"Divergent effects of octreotide on glucose tolerance in patients with acromegaly","volume":"36","author":"Hizuka","year":"1997","journal-title":"Intern Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/eje.1.02185","article-title":"Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly","volume":"155","author":"Steffin","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib80","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib81","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/BF03345491","article-title":"Effects of two different somatostatin analogs on glucose tolerance in acromegaly","volume":"25","author":"Ronchi","year":"2002","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib82","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors","volume":"91","author":"Ronchi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib83","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib84","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib85","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2008-2627","article-title":"Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib86","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib87","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11102-011-0361-9","article-title":"Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide","volume":"15","author":"Couture","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib88","first-page":"154","article-title":"Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia","volume":"35","author":"Cambuli","year":"2012","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.numecd.2016.02.001_bib89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1358\/dot.2013.49.2.1915142","article-title":"Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors","volume":"49","author":"Feelders","year":"2013","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.numecd.2016.02.001_bib90","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib91","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib92","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib93","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study","volume":"18","author":"Sheppard","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib94","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"Sesmilo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2265.2003.01795.x","article-title":"The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly","volume":"59","author":"Parkinson","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib96","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1096-6374(02)00083-7","article-title":"Growth hormone receptor antagonist improves insulin resistance in acromegaly","volume":"12","author":"Rose","year":"2002","journal-title":"Growth Hormone IGF Res"},{"key":"10.1016\/j.numecd.2016.02.001_bib97","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/eje.0.1490521","article-title":"Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant","volume":"149","author":"Drake","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib98","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jc.2005-0531","article-title":"Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist","volume":"90","author":"Jorgensen","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib99","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","article-title":"Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study","volume":"156","author":"Schreiber","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-007-0037-7","article-title":"Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA","volume":"10","author":"De Marinis","year":"2007","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib101","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib102","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib103","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib104","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","article-title":"Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly","volume":"94","author":"Higham","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib106","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-13-0032","article-title":"Effects of medical therapies for acromegaly on glucose metabolism","volume":"169","author":"Urbani","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib107","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/jc.2011-0654","article-title":"Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients","volume":"96","author":"Madsen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib108","first-page":"623","article-title":"A clinical and biochemical study of 12 cases of acromegaly with special reference to plasma I.R.I. and FFA on glibenclamide administration","volume":"19","author":"Kumar","year":"1971","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.numecd.2016.02.001_bib109","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1464-5491.2004.01299.x","article-title":"A case of secondary diabetes mellitus with acromegaly improved by pioglitazone","volume":"21","author":"Watanabe","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2265.2012.04411.x","article-title":"Pioglitazone in acromegaly \u2013 an open-label, prospective study","volume":"77","author":"Kim","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib111","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing's syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11102-005-1172-7","article-title":"Cardiovascular risk in Cushing's syndrome","volume":"7","author":"Arnaldi","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib113","first-page":"505","article-title":"Treatment of Cushing disease: overview and recent findings","volume":"21","author":"Mancini","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.numecd.2016.02.001_bib114","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1210\/jc.2004-0545","article-title":"Growth hormone and cardiovascular risk factors","volume":"90","author":"Gola","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib115","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib116","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-10-0125","article-title":"Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency","volume":"163","author":"Mazziotti","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib117","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4158\/EP.15.5.450","article-title":"American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.numecd.2016.02.001_bib118","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1590\/S0004-27302007000800013","article-title":"Subclinical Cushing's syndrome","volume":"51","author":"Terzolo","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.numecd.2016.02.001_bib119","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1210\/jc.2009-0806","article-title":"Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma","volume":"95","author":"Webb","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib121","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib122","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","article-title":"Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission","volume":"75","author":"Giordano","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.numecd.2016.02.001_bib123","first-page":"330","article-title":"Managing Cushing's disease: the state of the art","volume":"20","author":"Colao","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"10.1016\/j.numecd.2016.02.001_bib124","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MED.0b013e3283631809","article-title":"Update in the medical therapy of Cushing's disease","volume":"20","author":"Nieman","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.numecd.2016.02.001_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12345","article-title":"Efficacy of medical treatment in Cushing's disease: a systematic review","volume":"80","author":"Gadelha","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib126","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib128","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome","volume":"77","author":"Valassi","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.numecd.2016.02.001_bib129","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.numecd.2016.02.001_bib130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2016.02.001_bib131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-011-9549-z","article-title":"Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia","volume":"41","author":"Yoshida","year":"2012","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.numecd.2016.02.001_bib132","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1507\/endocrj.48.665","article-title":"Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH)","volume":"48","author":"Omori","year":"2001","journal-title":"Endocr J"},{"issue":"6081","key":"10.1016\/j.numecd.2016.02.001_bib133","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.2.6081.215","article-title":"Metyrapone in long-term management of Cushing's disease","volume":"2","author":"Jeffcoate","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2016.02.001_bib134","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing's syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib135","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib136","first-page":"3568","article-title":"Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)","volume":"86","author":"Chu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib137","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1530\/EJE-07-0792","article-title":"Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases","volume":"158","author":"Cassier","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.numecd.2016.02.001_bib138","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.numecd.2016.02.001_bib139","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.numecd.2016.02.001_bib140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.numecd.2016.02.001_bib141","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib142","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","article-title":"Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease","volume":"64","author":"Pecori Giraldi","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPARgamma ligand rosiglitazone in Cushing's disease","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.numecd.2016.02.001_bib144","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","article-title":"Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease","volume":"90","author":"Suri","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.numecd.2016.02.001_bib145","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","article-title":"Potential role for retinoic acid in patients with Cushing\u2019s disease","volume":"97","author":"Pecori Giraldi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib146","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/endo-110-4-1147","article-title":"Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture","volume":"110","author":"Schonbrunn","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.numecd.2016.02.001_bib147","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0168-8227(91)90052-F","article-title":"Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin","volume":"14","author":"Giustina","year":"1991","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.numecd.2016.02.001_bib148","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"Asireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2016.02.001_bib149","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib150","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","article-title":"Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy","volume":"94","author":"Ben-Shlomo","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib151","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000314352","article-title":"Medical treatment of Cushing\u2019s disease: somatostatin analogues and pasireotide","volume":"92","author":"Pedroncelli","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.numecd.2016.02.001_bib152","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1210\/en.2013-1820","article-title":"Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing\u2019s disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph trans differentiation","volume":"155","author":"Occhi","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.numecd.2016.02.001_bib153","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1210\/endo.140.8.6937","article-title":"Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells","volume":"140","author":"Mitra","year":"1999","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.numecd.2016.02.001_bib154","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/0091270011408727","article-title":"Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers","volume":"52","author":"Petersenn","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.numecd.2016.02.001_bib155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11102-006-0410-y","article-title":"Growth hormone deficiency in the adult","volume":"9","author":"Doga","year":"2006","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib156","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.numecd.2016.02.001_bib157","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib158","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11102-013-0539-4","article-title":"Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III trial","volume":"17","author":"Mackenzie Feder","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib159","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-014-0582-9","article-title":"Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations","volume":"18","author":"Trementino","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","article-title":"Extended treatment of Cushing's disease with pasireotide: results from a 2-year, phase II study","volume":"17","author":"Boscaro","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.numecd.2016.02.001_bib161","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2016.02.001_bib162","first-page":"390","article-title":"Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure","volume":"67","author":"Taghavi","year":"2012","journal-title":"Med J Malaysia"},{"issue":"4","key":"10.1016\/j.numecd.2016.02.001_bib163","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1463-1326.2011.01534.x","article-title":"Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults","volume":"14","author":"Gibson","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2016.02.001_bib164","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archinte.1994.00420010131015","article-title":"Glucocorticoids and the risk for initiation of hypoglycemic therapy","volume":"154","author":"Gurwitz","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib165","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s001250050847","article-title":"Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients","volume":"40","author":"Henriksen","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2016.02.001_bib166","first-page":"E995","article-title":"Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity","volume":"291","author":"Darmon","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1016\/j.numecd.2016.02.001_bib167","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid related hyperglycemia in hospitalized patients","volume":"12","author":"Donihi","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.numecd.2016.02.001_bib168","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bone.2009.06.006","article-title":"Vertebral fractures in males with type 2 diabetes treated with rosiglitazone","volume":"45","author":"Mancini","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.numecd.2016.02.001_bib169","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","article-title":"Drug-induced osteoporosis: mechanisms and clinical implications","volume":"123","author":"Mazziotti","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes \u2013 an interim analysis","volume":"357","author":"Home","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib171","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"van Raalte","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2016.02.001_bib172","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2169\/internalmedicine.52.8622","article-title":"Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy","volume":"52","author":"Matsuo","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.numecd.2016.02.001_bib173","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4158\/EP11371.OR","article-title":"A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone associated diabetes mellitus in hospitalized patients","volume":"18","author":"Dhital","year":"2012","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.numecd.2016.02.001_bib174","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3949\/ccjm.78a.10180","article-title":"Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them","volume":"78","author":"Lansang","year":"2011","journal-title":"Cleve Clin J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.numecd.2016.02.001_bib175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000314316","article-title":"Management of diabetes mellitus in Cushing's syndrome","volume":"92","author":"Newell-Price","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.numecd.2016.02.001_bib176","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-2007-955096","article-title":"Preserved GLP-1 effects in a diabetic patient with Cushing's disease","volume":"115","author":"Ritzel","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.numecd.2016.02.001_bib177","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.numecd.2016.02.001_bib178","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","article-title":"Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide","volume":"39","author":"Reznik","year":"2013","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.numecd.2016.02.001_bib179","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2016.02.001_bib180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1753-0407.12090","article-title":"Glucocorticoid-induced hyperglycemia","volume":"6","author":"Perez","year":"2014","journal-title":"J Diabetes"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947531600017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947531600017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T19:43:27Z","timestamp":1692215007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093947531600017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":180,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S093947531600017X"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2016.02.001","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Italian Society for the Study of Diabetes (SID)\/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}